Gene therapy: Role in myocardial protection

Handbook of Experimental Pharmacology

Volumn 176, Issue PART2, 2006, Pages 335-350

  Pachori, A S ^a   Melo, L G ^b   Dzau, V J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; COMPLEMENTARY DNA; HEME OXYGENASE 1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; REVIEW;

ANIMALS; CARDIOMEGALY; DNA, ANTISENSE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEME OXYGENASE-1; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39049187110     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-36028-x_11     Document Type: Article

References (61)

1. Antos CL, McKinsey TA, Frey N, KutschkeW, McAnally J, Shelton J, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase kinase 3 suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907-912 (Pubitemid 34106609)
2. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92:II365-II371
3. Asakura M, Kitakaze M, Taskashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, AsanumaH, Sanada S,Matsumara Y, Takeda H, Beppu S, TadaM, Hori M, Higashiyama S (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35-40 (Pubitemid 34101726)
4. Carden DL,GrangerDN(2000)Pathophysiology of ischemia-reperfusion injury.AmJPathol 190:255-266
5. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395 (Pubitemid 30208155)
6. Chen EP, Bittner HB, Davis RD, Van Trigt P, Folz RJ (1998) Physiological effects of extracellular superoxide dismutase transgene overexpression on myocardial function after ischemia and reperfusion injury. J Thorac Cardiovasc Surg 115:450-458
7. Chen H, Mohuczy D, Li D, Kimura B, Phillips MI, Mehta P, Mehta JL (2001) Protection against ischemia/reperfusion injury and myocardial dysfunction by antisenseoligodeoxynucleotide directed at angiotensin-converting enzyme mRNA. Gene Ther 8:804-810 (Pubitemid 32509795)
8. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno associated virus in humans. Gene Ther 6:1574-1583 (Pubitemid 29465516)
9. ColucciWS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L-25. (Pubitemid 27528444)
10. L D'Agostino RB, Russel MW, Huse DM, Ellison RC, Silbershantz H, Wilson PW, Hartz SC (2000) Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 139:272-281 (Pubitemid 30090804)
11. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989-2002-an overview. J Gene Med 6:597-602 (Pubitemid 40228075)
12. Feldman LJ, Steg G (1997) Optimal techniques for arterial gene transfer. Cardiovasc Res 35:391-404 (Pubitemid 27469400)
13. Funk M, Krumholz HM (1996) Epidemiologic and economic impact of advanced heart failure. J Cardiovasc Nurs 10:1-10
14. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu- Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534-539 (Pubitemid 26151517)
15. Givertz MM, Colucci WS (1998) New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 352:S134-S138
16. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL (2002) Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297 (Pubitemid 34260418)
17. Isner JM (2002) Myocardial gene therapy. Nature 415:234-239 (Pubitemid 34059530)
18. Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 12:951-957
19. Kaplitt MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, Makimura H, Kaplitt MJ, Strumpf RK, Diethrich EB (2000) Long term gene transfer in porcine myocardium after coronary infusion of and adeno-associated virus vector. Ann Thorac Surg 62:1669-1676
20. Klagsbrun M (1989) The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1:207-235
21. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baerga R, Anversa P (1997) Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 100:1991-1999 (Pubitemid 27459352)
22. Li Q, Bolli R, Qiu Y, Tang XL,Guo Y, French BA(2001) Gene therapywith extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 103:1893-1898 (Pubitemid 32328404)
23. LosordoDW,Vale PR, Symes JF,Dunnington CH, EsakofDD,MayskyM,AshareAB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804 (Pubitemid 29003959)
24. Mack CA, Patel SA, Schwarz EA,Zanzonico P,HahnRT,Hercil A, DevereuxRB,Goldsmith SJ, Christian TF, Sanborn TA,Kovesdi I,Hackett N, IsomOW, Crystal RG,Rosengart J (1998) Biological bypasswith the use of adenovirus-mediatedtransfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improvesmyocardial perfusion and function in the ischemic porcine heart. JThorac Cardiovasc Surg 115:168-177 (Pubitemid 28082163)
25. Mah C, Byrne BJ, Flotte TR (2002) Virus-based gene delivery systems. Clin Pharmacokinet 41:901-911 (Pubitemid 35168436)
26. Mann MJ, Dzau VJ (2000) Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106:1071-1075
27. Mann MJ,Whittemore AD, Donaldson MC, BelkinM, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ (1999) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 354:1493-1498 (Pubitemid 29502101)
28. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M,Komori K,Nakagawa K,HouX,Nagai Y, Hasegawa M, Sugimachi K, Sueishi K (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90:966-973 (Pubitemid 34633862)
29. McCarthy M (2001) Molecular decoy may keep bypass grafts open. Lancet 358:1703
30. McMurray JC, Pfeffer MA (2002) New therapeutic options in congestive heart failure. Circulation 105:2099-2106 (Pubitemid 34465274)
31. Mehta JL, Li DY (1999) Inflammation in ischemic heart disease: response to tissue injury or a pathogenic villain? Cardiovasc Res 43:291-299 (Pubitemid 29356367)
32. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan E, Griese DP, Dell'Acqua G, MannMJ,Oyama J,Yet SF, LayneMD, PerrellaAM,Dzau VJ (2002) Gene Therapy strategy for long term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105:602-607 (Pubitemid 34123435)
33. Melo LG, Pachori AS, Kong D, et al (2004) Gene and cell-based therapies for heart disease. FASEB J 18:648-663 (Pubitemid 38451787)
34. Monahan PE, Samulski RJ (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 6:433-440
35. MorishitaR, SugimotoT,AokiM,Kida I,TomitaN,MoriguchiA,MaedaK, SawaY,KanedaY, Higaki J, Ogihara T (1997) In vivo transfection of cis element "decoy" against nuclear factor factor ?B binding sites prevents myocardial infarction. Nat Med 3:894-899 (Pubitemid 27353450)
36. Niidome T, Huang L (2002) Gene therapy progress and prospects: non-viral vectors. Gene Ther 9:1647-1652 (Pubitemid 36104607)
37. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ (2002) Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 20:969-975 (Pubitemid 34547795)
38. Park JL, Lucchesi BR (1999) Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 68:1905-1912
39. Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted heart. Cardiovasc Res 46:307-315 (Pubitemid 30204603)
40. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E (1991) Progressive ventricular remodelling in rat myocardial infarction. Am J Physiol 260:H1406-H1414
41. Poston RS, Mann MJ, Hoyt EG, Ennen M, Dzau VJ, Robbins RC (1999) Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, non-toxic, highly efficient transfection method. Transplantation 68:825-832 (Pubitemid 29468201)
42. Robbins PD, Ghivizzani SC (1998) Viral vectors for gene therapy. Pharmacol Ther 80:35- 47:1998 (Pubitemid 28498200)
43. Sharif F, Daly K, Crowley J, O'Brien T (2004) Current status of catheter- and stent-based gene therapy. Cardiovasc Res 64:208-216 (Pubitemid 39361681)
44. Stein CA (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 108:641-644 (Pubitemid 32906188)
45. Stein EA (2002) Identification and treatment of individuals at high risk of coronary artery disease. Am J Med 112 Suppl 8A:3S-9S. (Pubitemid 34607387)
46. Stepkowski SM(2000) Development of antisense oligodeoxynucleotides for transplantation. Curr Opin Mol Ther 2:304-317 (Pubitemid 30436001)
47. Sutton MG, SharpeN(2000) Left ventricular remodeling aftermyocardial infarction. Pathophysiology and therapy. Circulation 101:2981-2988 (Pubitemid 30415891)
48. Sylven C, Sarkar N, Insulander P, Kenneback G, Blomberg P, Islam K, Drvota V (2002) Catheter-based transendocardial myocardial gene transfer. J Interv Cardiol 15:7-13 (Pubitemid 34218793)
49. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830-837 (Pubitemid 29526847)
50. TaigenT,Windt LJ, LimHW,Molkentin JD(2000)Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 97:1196-1201 (Pubitemid 30080835)
51. Tio RA, Tkebuchava T, Scheurermann TH, Lebherz C, Magner M, Kearny M, Esakof DD, Isner JM, Symes JF (1999) Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral blood flow to ischemicmyocardium. Hum Gene Ther 10:2953-2960
52. Ueda H, Sawa Y, Matsumoto K, Kitagawa-Sakakida S, Kawahira Y, Nakamura T, Kaneda Y, Matsuda H (1999) Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 67:1726-1731 (Pubitemid 29301318)
53. Ueno H, Li JJ, Masuda S, Qi Z, Yamamoto H, Takeshita A (1997) Adenovirus-mediated expression of the secreted formof basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 17:2453-2460 (Pubitemid 28015981)
54. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Narvanen O, Manninen H, Rasanen H, Hippelainen M, Alhava E, Yla-Herttuala S (2002) Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4:371-380 (Pubitemid 40277174)
55. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM (2001) Randomized, single-blind, placebo-controlled pilot study of catheter-basedmyocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103:2138-2143 (Pubitemid 32458322)
56. Ware JH, Simons M (1997) Angiogenesis in ischemic heart disease. Nat Med 3:158-164 (Pubitemid 27064699)
57. White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106:929-934
58. Williams RS, Benjamin IJ (2000) Protective responses of the ischemic myocardium. J Clin Invest 106:813-818
59. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847 (Pubitemid 28213628)
60. Yellon DM, Baxter GF (2000) Reperfusion injury revisited. Is there a role for growth factor signalling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245-249
61. Yla-Herttuala S, Alitalo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9:694-700